JP7357621B2 - 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体 - Google Patents

可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体 Download PDF

Info

Publication number
JP7357621B2
JP7357621B2 JP2020538535A JP2020538535A JP7357621B2 JP 7357621 B2 JP7357621 B2 JP 7357621B2 JP 2020538535 A JP2020538535 A JP 2020538535A JP 2020538535 A JP2020538535 A JP 2020538535A JP 7357621 B2 JP7357621 B2 JP 7357621B2
Authority
JP
Japan
Prior art keywords
formula
compound
base
salt
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511299A (ja
JP2021511299A5 (OSRAM
Inventor
ウォレス,デブラ・ジェーン
ジョウ,フェンガー
ワーン,ユーグワーン
崇 中井
カルナティ,ビシュヌ・バルダン・レッディ
シャイラー,ウェイン・シー
キセル,ウィリアム
シュエ,ソーン
ハシャシュ,アフマド
Original Assignee
サイクレリオン・セラピューティクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by サイクレリオン・セラピューティクス,インコーポレーテッド filed Critical サイクレリオン・セラピューティクス,インコーポレーテッド
Publication of JP2021511299A publication Critical patent/JP2021511299A/ja
Publication of JP2021511299A5 publication Critical patent/JP2021511299A5/ja
Priority to JP2023162922A priority Critical patent/JP7744955B2/ja
Application granted granted Critical
Publication of JP7357621B2 publication Critical patent/JP7357621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020538535A 2018-01-10 2019-01-10 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体 Active JP7357621B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023162922A JP7744955B2 (ja) 2018-01-10 2023-09-26 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
US62/615,678 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
CNPCT/CN2018/076982 2018-02-22
PCT/US2019/013060 WO2019140095A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023162922A Division JP7744955B2 (ja) 2018-01-10 2023-09-26 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体

Publications (3)

Publication Number Publication Date
JP2021511299A JP2021511299A (ja) 2021-05-06
JP2021511299A5 JP2021511299A5 (OSRAM) 2022-01-19
JP7357621B2 true JP7357621B2 (ja) 2023-10-06

Family

ID=65279655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538535A Active JP7357621B2 (ja) 2018-01-10 2019-01-10 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
JP2023162922A Active JP7744955B2 (ja) 2018-01-10 2023-09-26 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023162922A Active JP7744955B2 (ja) 2018-01-10 2023-09-26 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体

Country Status (16)

Country Link
US (5) US11274096B2 (OSRAM)
EP (3) EP4249469A3 (OSRAM)
JP (2) JP7357621B2 (OSRAM)
KR (3) KR20250048609A (OSRAM)
CN (3) CN111902410B (OSRAM)
AU (3) AU2019206560B2 (OSRAM)
CA (1) CA3087943A1 (OSRAM)
CL (3) CL2020001814A1 (OSRAM)
ES (1) ES2963447T3 (OSRAM)
IL (3) IL314714A (OSRAM)
JO (1) JOP20200165A1 (OSRAM)
MA (2) MA51565A (OSRAM)
MX (3) MX2020007364A (OSRAM)
SG (1) SG11202006311SA (OSRAM)
TW (2) TWI888947B (OSRAM)
WO (1) WO2019140095A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963563T3 (es) 2016-07-07 2024-03-27 Cyclerion Therapeutics Inc Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble
EP4249469A3 (en) 2018-01-10 2023-12-27 Cyclerion Therapeutics, Inc. Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
WO2024131860A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095697A1 (en) 2015-11-30 2017-06-08 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
JP2017528494A (ja) 2014-09-17 2017-09-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003405A1 (en) * 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
SI2970243T1 (sl) * 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
JP2017527605A (ja) * 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激剤
SG10202100168XA (en) 2016-07-07 2021-02-25 Cyclerion Therapeutics Inc Novel processes for preparation of soluble guanylate cyclase stimulators
ES2963563T3 (es) 2016-07-07 2024-03-27 Cyclerion Therapeutics Inc Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble
EP4249469A3 (en) 2018-01-10 2023-12-27 Cyclerion Therapeutics, Inc. Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528494A (ja) 2014-09-17 2017-09-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激剤
WO2017095697A1 (en) 2015-11-30 2017-06-08 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator

Also Published As

Publication number Publication date
KR102739727B1 (ko) 2024-12-05
EP4249469A3 (en) 2023-12-27
SG11202006311SA (en) 2020-07-29
MA71753A (fr) 2025-05-30
EP3737679B1 (en) 2023-09-06
WO2019140095A8 (en) 2020-06-18
CN111902410A (zh) 2020-11-06
EP4570797A3 (en) 2025-09-03
JOP20200165A1 (ar) 2022-10-30
AU2019206560A1 (en) 2020-07-30
TW202402741A (zh) 2024-01-16
US20230339928A1 (en) 2023-10-26
CL2022000904A1 (es) 2022-10-21
AU2025202281A9 (en) 2025-05-15
BR112020013985A2 (pt) 2020-12-01
JP2021511299A (ja) 2021-05-06
KR20250002720A (ko) 2025-01-07
KR20200106920A (ko) 2020-09-15
MA51565A (fr) 2020-11-18
EP3737679C0 (en) 2023-09-06
CN118184645A (zh) 2024-06-14
US20240391911A1 (en) 2024-11-28
MX2020007364A (es) 2020-11-18
ES2963447T3 (es) 2024-03-27
TWI821237B (zh) 2023-11-11
IL319883A (en) 2025-05-01
EP4249469A2 (en) 2023-09-27
US11274096B2 (en) 2022-03-15
CA3087943A1 (en) 2019-07-18
MX2023000045A (es) 2023-02-01
US11708361B2 (en) 2023-07-25
AU2025202281A1 (en) 2025-04-17
JP7744955B2 (ja) 2025-09-26
JP2023182647A (ja) 2023-12-26
US20220024909A1 (en) 2022-01-27
IL314714A (en) 2024-10-01
US20250361228A1 (en) 2025-11-27
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
CL2022000907A1 (es) 2022-10-21
AU2023270260B2 (en) 2026-01-29
CN118221665A (zh) 2024-06-21
TWI888947B (zh) 2025-07-01
AU2019206560B2 (en) 2023-08-24
IL275748B1 (en) 2024-09-01
WO2019140095A1 (en) 2019-07-18
US20210053962A1 (en) 2021-02-25
CN111902410B (zh) 2024-04-19
AU2023270260A1 (en) 2023-12-07
MX2023000044A (es) 2023-02-01
EP4570797A2 (en) 2025-06-18
EP3737679A1 (en) 2020-11-18
US12030874B2 (en) 2024-07-09
US12275724B2 (en) 2025-04-15
IL275748A (en) 2020-08-31
CL2020001814A1 (es) 2020-11-06
IL275748B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7744955B2 (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
EA048211B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
HK40103207A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
EA052114B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
EA045335B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
HK40031722A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK40031722B (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
BR112020013985B1 (pt) Novos processos e intermediários para a preparação de estimulantes de guanilato ciclase solúvel
WO2019161534A1 (en) Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230926

R150 Certificate of patent or registration of utility model

Ref document number: 7357621

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150